The Food and Drug Administration has granted approval to Eli Lilly’s new weight loss medication, introducing another pill option to a market currently led by injectable treatments and creating heightened rivalry with Novo Nordisk’s oral Wegovy product.
The pharmaceutical giant’s new drug, orforglipron marketed under the brand name Foundayo, is taken once daily and works by copying the hunger-reducing GLP-1 hormone that’s also targeted by Lilly’s popular injection tirzepatide, which is marketed as Mounjaro for diabetes treatment and Zepbound for weight management.
Financial analysts are weighing in with their perspectives on the new approval.
Equisights Research analyst Parth Talsania noted the competitive advantages of the new medication. “Absence of dosing restrictions (for Foundayo) is a clear adherence lever and should support stronger conversion among new-to-therapy patients,” Talsania said. “For Novo, the risk is not immediate share loss but incremental pressure on patient starts and pricing as Lilly expands access points. Overall, in a nutshell, we believe Lilly’s early approval of orforglipron strengthens its competitive positioning in GLP-1s.”
J.P. Morgan analyst Chris Schott expressed optimism about Lilly’s market position. “With this approval, we see the company (Lilly) well positioned with multiple potential sources of upside to numbers over the next several years,” Schott said. “We anticipate strong uptake of Foundayo… (but) expect inital Foundayo volumes to ramp more slowly relative to Oral Wegovy with a more significant inflection in 2H26/2027+. As such, we expect a solid initial volume ramp, but one that may trend below that of Oral Wegovy.”
Citi analyst Geoff Meacham highlighted the drug’s user-friendly features despite entering the market after its competitor. “Despite launching second behind Novo’s Wegovy pill, we think Foundayo’s superior ease-of-use more than offsets its 2.2% efficacy deficit and positions it to eventually capture the lion’s share of this rapidly expanding market. Crucially, the earlier-than-expected approval enables full participation in the upcoming broad Medicare access volume ramp,” Meacham said. “Clean safety label and crucially, no food restriction requirements that, altogether, underpin our 2026 $2.8 billion forecast.”
UBS analyst Michael Yee acknowledged market uncertainties while remaining positive about Lilly’s prospects. “There is some debate on how LLY’s oral market share will play out given consensus for oral Wegovy has moved up from (about) $800 million earlier this year given a solid launch so far. But all this bodes well for LLY,” Yee said.
Scotiabank analyst Louise Chen predicted international market success, stating: “We expect orforglipron to be more popular in most markets outside the U.S.”
Cantor Fitzgerald analyst Carter Gould focused on competitive dynamics and market entry strategy. “While it’s unclear how broad commercial access will be ‘out of the gate’, or how it will ramp in those first few months, we see this as seizing some of the attention on the pricing front from Novo, and helping drive conversations and conversion,” Gould said.
